Plasma DNA methylation: a potential biomarker for stratification of liver fibrosis in non-alcoholic fatty liver disease
Conclusions
Differential DNA methylation at the PPAR promoter can be detected within the pool of cell-free DNA of human plasma. With further validation, plasma DNA methylation of PPAR could potentially be used to non-invasively stratify liver fibrosis severity in patients with NAFLD. Plasma DNA methylation signatures reflect the molecular pathology associated with fibrotic liver disease.
Source: Gut - Category: Gastroenterology Authors: Hardy, T., Zeybel, M., Day, C. P., Dipper, C., Masson, S., McPherson, S., Henderson, E., Tiniakos, D., White, S., French, J., Mann, D. A., Anstee, Q. M., Mann, J. Tags: Open access Hepatology Source Type: research
More News: Alcoholism | Cirrhosis | Fatty Liver Disease (FLD) | Gastroenterology | Genetics | Liver | Liver Disease | Non-alcoholic Fatty Liver Diseases (NAFLD) | Pathology | Study | Urology & Nephrology